Transmedics Group Stock Performance
| TMDX Stock | USD 129.84 1.32 1.03% |
The entity has a beta of 0.77, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, TransMedics' returns are expected to increase less than the market. However, during the bear market, the loss of holding TransMedics is expected to be smaller as well. At this point, TransMedics Group has a negative expected return of -0.0037%. Please make sure to validate TransMedics' downside variance, and the relationship between the total risk alpha and daily balance of power , to decide if TransMedics Group performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days TransMedics Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental indicators, TransMedics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 1.03 | Five Day Return (7.73) | Year To Date Return 5.83 | Ten Year Return 480.68 | All Time Return 480.68 |
1 | 1 Growth Stock Im Thankful for -- and the Unstoppable Stock Im Buying Using the Lessons It Taught Me | 11/25/2025 |
2 | Disposition of 920 shares by Gerardo Hernandez of TransMedics at 139.62 subject to Rule 16b-3 | 12/04/2025 |
3 | TransMedicsGroup, Inc. ABullCase Theory | 12/08/2025 |
4 | How Is The Market Feeling About TransMedics Group Inc | 01/02/2026 |
5 | Park Avenue Securities LLC Increases Holdings in TransMedics Group, Inc. TMDX | 01/15/2026 |
6 | TransMedics Group Shares Down 4.3 percent Should You Sell | 01/21/2026 |
7 | TransMedics Group Advances Organ Care in Nasdaq 100 Composition | 01/28/2026 |
8 | Did Nasdaq 100 Inclusion Just Shift TransMedics Groups Organ-Transplant Tech Investment Narrative | 01/30/2026 |
9 | Brown Capital Management LLC Reduces Stock Position in TransMedics Group, Inc. TMDX - MarketBeat | 02/03/2026 |
10 | TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 | 02/10/2026 |
11 | Assessing TransMedics Group Valuation After FDA IDE Approval For ENHANCE Heart Trial | 02/13/2026 |
| Begin Period Cash Flow | 395.3 M | |
| Total Cashflows From Investing Activities | -129.3 M |
TransMedics | Build AI portfolio with TransMedics Stock |
TransMedics Relative Risk vs. Return Landscape
If you would invest 13,347 in TransMedics Group on November 19, 2025 and sell it today you would lose (363.00) from holding TransMedics Group or give up 2.72% of portfolio value over 90 days. TransMedics Group is currently does not generate positive expected returns and assumes 2.9365% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than TransMedics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TransMedics Target Price Odds to finish over Current Price
The tendency of TransMedics Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 129.84 | 90 days | 129.84 | about 60.63 |
Based on a normal probability distribution, the odds of TransMedics to move above the current price in 90 days from now is about 60.63 (This TransMedics Group probability density function shows the probability of TransMedics Stock to fall within a particular range of prices over 90 days) .
TransMedics Price Density |
| Price |
Predictive Modules for TransMedics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as TransMedics Group. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of TransMedics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
TransMedics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. TransMedics is not an exception. The market had few large corrections towards the TransMedics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold TransMedics Group, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of TransMedics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.09 | |
β | Beta against Dow Jones | 0.77 | |
σ | Overall volatility | 8.60 | |
Ir | Information ratio | 0.02 |
TransMedics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of TransMedics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for TransMedics Group can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| TransMedics Group generated a negative expected return over the last 90 days | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Assessing TransMedics Group Valuation After FDA IDE Approval For ENHANCE Heart Trial |
TransMedics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of TransMedics Stock often depends not only on the future outlook of the current and potential TransMedics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. TransMedics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 35.2 M | |
| Cash And Short Term Investments | 336.6 M |
TransMedics Fundamentals Growth
TransMedics Stock prices reflect investors' perceptions of the future prospects and financial health of TransMedics, and TransMedics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TransMedics Stock performance.
| Return On Equity | 0.32 | ||||
| Return On Asset | 0.0693 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 4.49 B | ||||
| Shares Outstanding | 34.17 M | ||||
| Price To Book | 12.49 X | ||||
| Price To Sales | 7.83 X | ||||
| Revenue | 441.54 M | ||||
| Gross Profit | 341.4 M | ||||
| EBITDA | 69.95 M | ||||
| Net Income | 35.46 M | ||||
| Cash And Equivalents | 204.46 M | ||||
| Cash Per Share | 6.41 X | ||||
| Total Debt | 518.29 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 12.11 X | ||||
| Book Value Per Share | 10.40 X | ||||
| Cash Flow From Operations | 48.8 M | ||||
| Earnings Per Share | 2.54 X | ||||
| Market Capitalization | 4.44 B | ||||
| Total Asset | 804.08 M | ||||
| Retained Earnings | (468.24 M) | ||||
| Working Capital | 437.3 M | ||||
About TransMedics Performance
Evaluating TransMedics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if TransMedics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if TransMedics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 108.89 | 103.44 | |
| Return On Tangible Assets | 0.04 | 0.04 | |
| Return On Capital Employed | 0.05 | 0.05 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.18 | 0.33 |
Things to note about TransMedics Group performance evaluation
Checking the ongoing alerts about TransMedics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TransMedics Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TransMedics Group generated a negative expected return over the last 90 days | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Assessing TransMedics Group Valuation After FDA IDE Approval For ENHANCE Heart Trial |
- Analyzing TransMedics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TransMedics' stock is overvalued or undervalued compared to its peers.
- Examining TransMedics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TransMedics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of TransMedics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TransMedics' stock. These opinions can provide insight into TransMedics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for TransMedics Stock Analysis
When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.